IDO1 and neoplasm: Furthermore, antisense-mediated reduction in the amount of IDO induced by IFN gamma reduced cellular NAD+ in A549 human tumor cell line by approximately 60% (Fig. 2D), similar to the reduction observed in vitro after treatment with FK866 (a pharmacological inhibitor of NAD+)[37].